PMID: 9547135Apr 18, 1998Paper

Long-term risperidone treatment in bipolar disorder: 6-month follow up

International Clinical Psychopharmacology
S Nassir Ghaemi, G S Sachs

Abstract

Antipsychotic agents, such as clozapine and risperidone, have been reported to be beneficial in the treatment of some bipolar patients. Many bipolar patients experience 'breakthrough episodes' of mood disorder, with mania or depression recurring despite adequate ongoing levels of one or more mood-stabilizing medications. There are no controlled studies of breakthrough episodes, and there is little open experience to guide clinicians in pharmacotherapy of breakthrough episodes. This report describes the outcome of adjunctive risperidone treatment in breakthrough episodes of bipolar disorder. We assessed the outcome of openly adding risperidone to the medication regimen of 12 outpatients with bipolar disorder, type I, who suffered breakthrough episodes despite adequate maintenance medication (lithium, valproate, or carbamazepine, or a combination of these). Prospective ratings were made at each clinical visit using the Clinical Global Impressions and Global Assessment of Functioning scales. Patients received risperidone for a mean of 6.0 months (23.96 weeks, range 0.5-72 weeks) at a mean dose of 2.75 mg/day (range 1-4.5 mg/day). Four patients discontinued medication (two because of lack of efficacy at weeks 6 and 64, and two beca...Continue Reading

Citations

Jan 30, 2002·Current Psychiatry Reports·William M McDonald, John Wermager
Dec 21, 2000·Journal of Affective Disorders·C L Bowden von Knorring L
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank-Gerald Pajonk
Dec 12, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·E VietaC Gastó
Jul 6, 2000·The Australian and New Zealand Journal of Psychiatry·S BleichE Rüther
Aug 6, 1999·Journal of the American Academy of Child and Adolescent Psychiatry·J A FrazierS Shapiro
Feb 24, 2001·International Clinical Psychopharmacology·I Schweitzer
Sep 18, 2001·Drugs·M BerkM Vorster
Dec 7, 2002·CNS Drugs·Gin S MalhiShahzad Salim
Feb 4, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Laksami N YathamArun Ravindran
Apr 1, 1999·Indian Journal of Psychiatry·P N Kumar
Nov 11, 2005·Expert Review of Neurotherapeutics·Eduard Vieta
Jul 5, 2005·Expert Opinion on Investigational Drugs·N A Keks, C Culhane
Oct 2, 2003·Expert Opinion on Investigational Drugs·Michael Berk, Seetal Dodd
Jul 14, 2000·Current Medical Research and Opinion·B Green
Nov 11, 2003·Perspectives in Psychiatric Care·Susan McCabe
Dec 18, 2001·Biological Psychiatry·P F Buckley
Oct 6, 2000·Biological Psychiatry·M E Thase, G S Sachs
Oct 6, 2000·Biological Psychiatry·G S Sachs, M E Thase
Mar 14, 2013·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeUNKNOWN WFSBP Task Force on Treatment Guidelines for Bipolar Disorders
Feb 18, 2005·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Lev BotvinikIsaac Schweitzer
Apr 6, 2004·The Psychiatric Clinics of North America·Elizabeth B WellerRonald A Weller
Nov 7, 1999·The Psychiatric Clinics of North America·L SanchezR Weller
Jan 6, 2000·The Australian and New Zealand Journal of Psychiatry·P B Mitchell
Jul 2, 2005·Journal of Psychiatric Practice·T D Perera, S H Lisanby
Jun 13, 2003·The Journal of Head Trauma Rehabilitation·Elie Paul ElovicJoseph H Ricker
Jun 15, 2005·Bipolar Disorders·Lakshmi N YathamUNKNOWN Canadian Network for Mood and Anxiety Treatments
May 18, 2005·Psychiatry and Clinical Neurosciences·Michael BerkLesley Berk
May 3, 2002·Molecular Psychiatry·P E KeckM Tohen
Mar 26, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Chantal Henry, Jacques Demotes-Mainard
Oct 28, 2010·Expert Review of Neurotherapeutics·William V Bobo, Richard C Shelton
Aug 10, 1999·Journal of Clinical Psychopharmacology·S N Ghaemi, F K Goodwin
Jul 2, 2003·Journal of Clinical Psychopharmacology·Gary S Sachs
Jun 5, 2003·Bipolar Disorders·Mukund GnanadesikanAlan J Gelenberg
Feb 28, 2003·Psychopharmacology·Paolo BrambillaJair C Soares
Sep 14, 2004·CNS Spectrums·Claudia F BaldassanoJohn P O'Reardon
Feb 18, 2005·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Edmond Chiu
May 1, 2004·Acta Psychiatrica Scandinavica·G J R Mensink, C J Slooff
Jan 6, 2021·Journal of Neurodevelopmental Disorders·Alexander KolevzonJudith Jaeger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.